^
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A1 - Approval
    RET mutation
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: A1 - Approval
    RET mutation
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Medullary Carcinoma
    dacarbazine
    Sensitive: A2 - Guideline
    No biomarker
    Thyroid Gland Medullary Carcinoma
    denosumab
    Sensitive: A2 - Guideline
    No biomarker
    Thyroid Gland Medullary Carcinoma
    cabozantinib tablet
    Sensitive: A2 - Guideline
    TMB-H
    Thyroid Gland Medullary Carcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    RET M918T
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A2 - Guideline
    RAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A2 - Guideline
    KRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: B - Late Trials
    NRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: B - Late Trials
    KRAS mutation
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: B - Late Trials
    RET mutation
    Thyroid Gland Medullary Carcinoma
    TPX-0046
    Sensitive: C2 – Inclusion Criteria
    RET mutation
    Thyroid Gland Medullary Carcinoma
    BOS-172738
    Sensitive: C2 – Inclusion Criteria
    RET V804*
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C3 – Early Trials
    RET C634*
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C3 – Early Trials
    RET C634R
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: C3 – Early Trials
    RET V804M
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C3 – Early Trials
    RET V804L
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C3 – Early Trials
    RET mutation
    Thyroid Gland Medullary Carcinoma
    RET inhibitor
    Sensitive: C3 – Early Trials
    RET V804M + RET M918T + RET G810 + RET Y806
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Resistant: C4 – Case Studies
    NF1 mutation
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive: C4 – Case Studies
    ATM S978fs*12
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive: C4 – Case Studies
    ATM L804fs*4
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive: C4 – Case Studies
    RET C620R
    Thyroid Gland Medullary Carcinoma
    everolimus
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    everolimus
    Sensitive: C4 – Case Studies
    RET C618R
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: C4 – Case Studies
    RET C634F
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: C4 – Case Studies
    ATM S978fs*12
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: C4 – Case Studies
    ATM L804fs*4
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: C4 – Case Studies
    RET L629P
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C4 – Case Studies
    RET D631_R635delinsG
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C4 – Case Studies
    RET V637R
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C4 – Case Studies
    RET exon 11 deletion
    Thyroid Gland Medullary Carcinoma
    sorafenib + tipifarnib
    Sensitive: C4 – Case Studies
    RET V804M + M918T
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    sunitinib
    Sensitive: C4 – Case Studies
    RET Y900_S904delinsP
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C4 – Case Studies
    CCDC6-ALK fusion
    Thyroid Gland Medullary Carcinoma
    alectinib
    Sensitive: C4 – Case Studies
    RET C634W
    Thyroid Gland Medullary Carcinoma
    RAF265
    Sensitive: D – Preclinical
    RET M918T
    Thyroid Gland Medullary Carcinoma
    AMG 706
    Resistant: D – Preclinical
    RET C634W
    Thyroid Gland Medullary Carcinoma
    AMG 706
    Resistant: D – Preclinical
    RET C634W
    Thyroid Gland Medullary Carcinoma
    lenvatinib
    Sensitive: D – Preclinical
    KRAS G12R
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    BRAF mutation
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    PTEN mutation
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    RET mutation
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    NRAS mutation
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    KRAS mutation
    Thyroid Gland Medullary Carcinoma
    RTB101 + RAF265
    Sensitive: D – Preclinical
    RET C634W
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: D – Preclinical
    BRAF V600E
    Thyroid Gland Medullary Carcinoma
    CI-1040
    Sensitive: D – Preclinical
    RET C634Y
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: D – Preclinical